Results 91 to 100 of about 14,957,077 (381)

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

CAR-T cell manufacturing: Major process parameters and next-generation strategies

Journal of Experimental Medicine
The success of CAR-T cell therapies is dependent on effective cell manufacturing that impacts product safety, efficacy, and patient accessibility. Here, we discuss major process parameters of autologous CAR-T cell manufacturing, regulatory considerations,
Melanie Ayala Ceja, M. Khericha, Caitlin M Harris, Cristina Puig-Saus, Y. Chen   +4 more
semanticscholar   +1 more source

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells [PDF]

, 2017
Autologous T cells engineered to express chimeric antigen receptor against the B cell antigen CD19 (CAR19) are achieving marked leukemic remissions in early-phase trials but can be difficult to manufacture, especially in infants or heavily treated ...
Adams, S, Ahsan, G, Amrolia, P, Butler, K, Chan, L, Chiesa, R, Farzeneh, F, Ghorashian, S, Gilmour, K, Inglott, S, Lucchini, G, Mifsud, W, Peggs, KS, Pinner, D, Pule, M, Qasim, W, Rivat, C, Samarasinghe, S, Somana, K, Stafford, S, Thrasher, AJ, Veys, P, Vora, A, Wright, G, Zhan, H   +24 more
core   +1 more source

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. [PDF]

, 2020
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response.
Chari, Ajai, Mezzi, Khalid, Scott, Emma, Shah, Nina, Usmani, Saad Z   +4 more
core   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy

Frontiers in Immunology
Adoptive cell therapy (ACT) employing chimeric antigen receptor (CAR) engineering represents a transformative advancement in cancer immunotherapy. CAR-T cell therapies have demonstrated significant clinical success in hematological malignancies, yet ...
Yingjie Hou, Yingjie Hou, Shihua Hu, Chong Liu, Chong Liu, Xin Chen, Xin Chen, Yuru Wang, Yuru Wang, Youzherui Li, Youzherui Li, Zihe Fu, Chunjing Feng, Chunjing Feng, Yanhua Gong, Zichuan Liu, Zichuan Liu, Shouchun Peng, Shouchun Peng   +18 more
doaj   +1 more source

Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Nature Medicine
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies.
C. Brown, Jonathan C. Hibbard, D. Alizadeh, M. Blanchard, H. Natri, Dongrui Wang, J. Ostberg, B. Aguilar, Jamie R. Wagner, Jinny A. Paul, R. Starr, Robyn A Wong, Wuyang Chen, Noah Shulkin, Maryam Aftabizadeh, Aleksandr Filippov, Ammar Chaudhry, J. Ressler, Julie Kilpatrick, Paige Myers-McNamara, Mike Chen, Leo D Wang, Russell C. Rockne, Joseph Georges, J. Portnow, Michael Barish, M. D’Apuzzo, Nicholas E. Banovich, Stephan Forman, B. Badie   +29 more
semanticscholar   +1 more source

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia [PDF]

, 2015
Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose limiting toxicities.
Anne Angiolillo, Haneen Shalabi, Terry J. Fry   +2 more
core   +3 more sources